News FAMHP

There are 14 result(s) found based on your search criteria

11-14 from 14 result(s)

Flash VIG-news: domperidone: no longer approved for use in children due to a lack of efficacy

The use of domperidone in newborns, infants, children (under 12) and adolescents weighing less than 35kg is no longer approved at European level. A new clinical study has demonstrated a lack of efficacy of the medical product.

PRAC March 2019 – Start of referral : Review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine

During its meeting of March 2019, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has started a review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine.

Now there is also an online reporting form available for patient reporting of side effects of drugs

Reporting side effects contributes to the monitoring of the safety of medicines. To stimulate patient reporting of side effects, there is now a user-friendly online reporting form available.

Flash VIG-news: LYNPARZA® (olaparib): risk of medication errors with new pharmaceutical form

LYNPARZA® capsules (50 mg) and LYNPARZA® tablets (100 mg and 150 mg) are not interchangeable on a milligram by milligram basis due to variations in dose/dosage and the biological availability of each formulation.

11-14 from 14 result(s)